Identifying early signs of Parkinson's in Gaucher mutation carriers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to identify a sub-population of individuals carrying GBA1 mutations who are at increased risk of developing Parkinson's disease. Participants will undergo a comprehensive evaluation involving various non-invasive tests, including sensory assessments, blood tests, blood pressure measurements, brain ultrasounds, and neurological evaluations. The study will compare the findings of GBA1 mutation carriers with diagnosed Gaucher patients and healthy individuals who do not carry the mutation. The goal is to detect early signs of Parkinson's disease that may appear up to twenty years before diagnosis.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Willing to participate

Exclusion Criteria:

* PD patients
* Dementia

Where it's running

• Michal Becker- Cohen
  Jerusalem, Please Select..., Israel Recruiting

Study contacts

• Principal investigator: Ari Zimran, MD — Shaare Zedek Medical Center
• Study coordinator: Ari Zimran, MD
• Email: azimran@gmail.com
• Phone: +972-509149149

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• FLT201 gene therapy for adults with Gaucher disease type 1

  This trial tests a one-time gene therapy called FLT201 in adults with Gaucher disease type 1 who have been on stable enzyme replacement or substrate reduction therapy to see if they can stop those treatments and keep their blood counts and disease control stable.

  Recruiting at 25 sites Phase 3 Spur Therapeutics · Los Angeles, California and 31 other locations · NCT07223944

• Evaluating LY-M001 Injection for Treating Type I Gaucher Disease

  This study is testing a new gene therapy injection called LY-M001 to see if it can safely help adults with Type I Gaucher Disease feel better.

  Recruiting at 3 sites Phase 1/2 Lingyi Biotech Co., Ltd. · Guangzhou, Guangdong and 2 other locations · NCT06818838

• Do Quercefit® or Ubiqsome™ help with aging and metabolic health in adults 50–75?

  This study tests whether Quercefit® or Ubiqsome™ can improve aging markers, blood sugar, and heart health in sedentary adults aged 50–75 compared with a placebo.

  Recruiting Applied Science & Performance Institute · Tampa, Florida · NCT07760506

• NVTIA Ergothioneine for Healthy Aging and Skin Health

  This study tests whether taking NVTIA Ergothioneine daily for 12 weeks helps healthy adults age more gracefully and keeps skin looking and feeling better compared with a placebo.

  Recruiting European Life Science Research Association · Dhaka · NCT07750002

• Miricell supplementation and markers of healthy aging

  This trial tests whether taking Miricell once daily for 12 weeks improves cellular health and brain/metabolic indicators in adults aged 40–70 compared with a placebo.

  Recruiting Nutraland USA, Inc. · Canfield, Ohio · NCT07675200

• Does daily lean beef support brain health in older adults

  In healthy adults aged 65 and up, this study tests whether eating lean beef every day for two weeks can influence brain health markers compared with a non-beef, protein-matched option.

  Recruiting South Dakota State University · Brookings, South Dakota · NCT07623785

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.